atacicept   Click here for help

GtoPdb Ligand ID: 9517

Synonyms: TACI-Fc | TACI-Ig
Immunopharmacology Ligand
Comment: Atacicept is a recombinant fusion protein that was designed to inhibit B cells, and which was investigated as an intervention in autoimmune diseases [2]. Mechanistically atacicept neutralises the function of two important B-cell activating factors, BAFF (BLyS) and APRIL. Structurally atacicept contains the BLyS/APRIL-binding extracellular portion of the TACI receptor fused to a modified Fc from human IgG1 [4]. One of the important functions of these two factors in autoimmune disease is their ability to induce proliferation of plasma cells and thus increase Ig production, in particular the production of destructive anti-self antibodies. However, this modality has proven ineffective in autoimmune diseases in clinical studies. As of June 2021 atacicept was being deployed for IgA nephropathy.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for atacicept is claimed in patent WO2002094852 [8].
Bioactivity Comments
WO2002094852 provides binding data for BAFF but not for APRIL, ZNTF4 and ZNTF2 respectively in this patent [8].
Other ligands which bind to or alter the activity of this ligand
Key to terms and symbols Click column headers to sort
Ligand Sp. Type Action Value Parameter Concentration range (M) Reference
BAFF {Sp: Human} Peptide Primary target of this compound Hs None Binding 9.9 – 10.1 pKd - 8
pKd 9.9 – 10.1 (Kd 1.35x10-10 – 9x10-11 M) [8]
Description: Competitive binding to [125I]BAFF.